NCT05088070View on ClinicalTrials.gov

Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

July 30, 2023

Study Completion Date

July 30, 2023

Conditions
Solid Tumor
Interventions
DRUG

SPH 3348

2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach

DRUG

SPH 3348

1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach

DRUG

SPH 3348

2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

DRUG

SPH 3348

4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

DRUG

SPH 3348

6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

DRUG

SPH 3348

8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

Trial Locations (1)

233004

The First Affliated Hospital of Bengbu Medical College, Bengbu

All Listed Sponsors
lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

NCT05088070 - Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors | Biotech Hunter | Biotech Hunter